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COST-EFFECTIVENESS OF TIROFIBAN PLUS 
HEPARIN AS COMPARED WITH HEPARIN ONLY 
IN TREATING UNSTABLE ANGINA
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Department of Pharmaceutical Economics and Policy, School 
of Pharmacy, University of Southern California, Los Angeles, 
CA, USA
Anti-thrombotic therapy improves the prognosis of pa-
tients with unstable angina. Two clinical trials have eval-
uated the clinical efficacy of tirofiban or tirofiban plus
heparin in the treatment of unstable angina. However,
high price for tirofiban prompts the question of whether
the additional effectiveness is worth the additional drug
cost. OBJECTIVE: This medical decision analytic model
is to investigate the cost-effectiveness of tirofiban plus he-
parin in treating unstable angina relative to heparin only.
METHOD: Parameters of treatment efficacy used in the
cost-effectiveness model were primarily from the report
of PRISM-PLUS (the Platelet Receptor Inhibition in Is-
chemic Syndrome Management in Patients Limited by
Unstable Signs and Syndrome) trial. Other parameters
(cost, life expectancy, and quality of life) were cited from
the published literature. The time frame for this model is
1-month initial episode of unstable angina and 1-year fol-
low-up. It was assumed that there was no additional cost
difference between two groups after one-year follow-up.
Effectiveness was measured as quality adjusted life years
(QALYs). RESULTS: A patient in tirofiban plus heparin
group had both higher total costs ($25,467 versus
$24,805) and a lower mortality rate (5.89% versus
6.83%) than a patient in heparin only group. The incre-
mental cost-effectiveness ratio was $10,417/QALY at
3% discount rate. In the sensitivity analysis, the incre-
mental cost-effectiveness ratio was only sensitive to the
tirofiban acquisition cost. CONCLUSION: Treating un-
stable angina with tirofiban plus heparin is cost-effective
compared with the traditional heparin-only therapy.
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Whether insurance status affects medical care is a ques-
tion with particular relevance for the large US population
segment treated for congestive heart failure (CHF). OB-
JECTIVE: To understand the evaluation and effects of in-
surance status on resource use (costs and procedure in-
tensity) and other outcomes (length of stay and inpatient
mortality) experienced by in-patients with CHF. METH-
ODS: Multivariate analysis of hospital records (UB-92
abstracts) of patients under age 65 from acute care facili-
ties in fourteen states across the US. Unique regression-
based risk adjustment methods control for clinical, de-
mographic, and selection factors in order to isolate the
effects of insurance status on the variables of interest.
Also inferred are the insurance-status specific marginal
effects of CHF as a secondary diagnosis on the outcomes
and resource use for those patients admitted for other
conditions. RESULTS: The effects of insurance status on
resource use (vs. adverse outcomes) are significant. With
the exception of traditional Blue Cross virtually all private
insurance pay-outs and lengths of stay were significantly
lower than public payors. Comparing high-intensity pro-
cedures (e.g. cardiac catheterization) to lower intensity
tests (e.g. ultrasound) indemnity insurers and PPOs dis-
played the greatest intensity, while public payors showed
the lowest intensity rates. The marginal effects of CHF are
substantial, raising length of stay and treatment cost by
25% to 40%, depending on insurance status. CONCLU-
SION: Insurance status is correlated with treatment of
CHF, but effects are complicated. For example, even though
public payors tend to have patients with longer lengths of
stay and higher costs, they also tend to get lower treat-
ment intensity. Some of these effects can be explained
only by noting that certain relevant patient attributes not
controlled by the risk analysis (such as access to ambula-
tory care) must vary systematically with insurance status.
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OBJECTIVES: For patients with hypertension, successful
pharmacologic treatment depends on the efficacy of the
drug as well as its tolerability. The purpose of this study
was to develop and test a rating system that characterizes
an agent’s effectiveness in terms of clinical efficacy rela-
tive to patient perception of tolerability. The Perceptual
Effectiveness Index (PEI) is a 4-point ordinal scale, where
0 indicates the agent is not effective in controlling blood
pressure, regardless of side effects, and 1 indicates opti-
mal effectiveness, i.e., blood pressure control with mini-
mal to no side effects. METHODS: The PEI was tested in
243 patients participating in an 8-week, multicenter,
double-blind trial comparing the efficacy, safety and tol-
erability of candesartan cilexetil versus amlodipine. RE-
SULTS: Mean age of the sample was 53 years (12);
54% were male. Of the 202 who achieved control of
their hypertension, 62 (31%) experienced side effects
that were classified as moderate to high impact; 33
(16%) experienced side effects with moderate impact,
and 29 (14%) fell into the high impact group. There was
a statistically significant relationship between these PEI
categories and global HRQL (P  0.001), utility (visual
analog scale-transformed) (P  0.001), and satisfaction
